Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Concentration risk — Customer: small number of distributors.
Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE (FDA-approved February 2023 for geographic atrophy) and EMPAVELI (FDA-approved May 2021 for PNH, July 2025 for C3G/IC-MPGN). U.S. product revenue totaled $689.3 million in... Read more
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Concentration risk — Customer: small number of distributors. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Apellis Pharmaceuticals, Inc.
Latest news
- NEWS Cantor Fitzgerald Suspends Neutral Rating on Apellis Pharmaceuticals — benzinga May 15, 2026 negative
- NEWS Why Is Biogen Stock Falling Thursday? — benzinga May 14, 2026 neutral
- NEWS Biogen Stock Gains Despite Extended FDA Review For Alzheimer's Therapy — benzinga May 8, 2026 neutral
- NEWS Apellis Pharmaceuticals Q1 EPS $0.15 Beats $(0.36) Estimate, Sales $268.295M Beat $205.185M Estimate — benzinga May 7, 2026 positive
- NEWS Remitly Global Set To Join S&P SmallCap 600 Will Replace Apellis Pharmaceuticals — benzinga May 7, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductSYFOVRE10-K Item 1A: 'Our prospects depend substantially upon the commercial success of SYFOVRE'
- HIGHCustomersmall number of distributors10-K Item 1A: 'Sales to a small number of distributors account for substantially all our gross revenue related to SYFOVRE during the year ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-05-14Item 5.01HIGHBiogen completed acquisition of Apellis on May 14, 2026. Tender offer expired May 13, 2026; Apellis became a wholly-owned Biogen subsidiary at $41.00/share cash plus CVR up to $4.00. Change of control.SEC filing →
- 2026-03-31Item 1.01MEDIUMApellis entered Agreement and Plan of Merger with Biogen Inc. and subsidiary Aspen Purchaser Sub on March 31, 2026. Offer price: $41.00/share cash plus CVR up to $4.00. Subject to tender conditions.SEC filing →
- 2026-05-04Item 5.02LOWCompensation committee approved amended Executive Separation Benefits and Retention Plan on April 28, 2026, effective at merger closing. Provides accelerated vesting for unvested Converted Options and RSU Awards upon qualifying termination. No officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $41.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: SYFOVRE; Concentration risk — Customer: small number of distributors. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $40.32 (-1.8%), stop $40.91 (−0.4%), A.R:R -0.9:1. Score 5.9/10, moderate confidence.
Take-profit target: $40.32 (-1.7% upside). Target $40.32 (-1.8%), stop $40.91 (−0.4%), A.R:R -0.9:1. Stop-loss: $40.91.
Concentration risk — Product: SYFOVRE; Concentration risk — Customer: small number of distributors; Analyst target reached - limited upside remaining.
Apellis Pharmaceuticals, Inc. trades at a P/E of 38.3 (forward -130.5). TrendMatrix value score: 3.2/10. Verdict: Hold.
27 analysts cover APLS with a consensus score of 3.4/5. Average price target: $41.
What does Apellis Pharmaceuticals, Inc. do?Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE (FDA-approved...
Apellis Pharmaceuticals is a commercial-stage biopharma with two marketed complement inhibitors: SYFOVRE (FDA-approved February 2023 for geographic atrophy) and EMPAVELI (FDA-approved May 2021 for PNH, July 2025 for C3G/IC-MPGN). U.S. product revenue totaled $689.3 million in 2025, with Sobi holding exclusive ex-U.S. rights for systemic pegcetacoplan.